CTL 901

Drug Profile

CTL 901

Alternative Names: Cancer vaccine - Innovata plc; Cancer vaccine - ML Laboratories; Cancer vaccine gene therapy - Cobra Therapeutics; Cancer vaccine gene therapy - Innovata plc

Latest Information Update: 17 Sep 2007

Price : $50

At a glance

  • Originator Innovata
  • Developer Vectura
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Jan 2007 Innovata has been acquired by Vectura
  • 14 Jul 2005 Innovata Biomed has merged with ML Laboratories to form Innovata
  • 13 Jan 2004 Phase-I clinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top